Lung-on-Chip Stretching Platform for Parallel Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing microfluidic chips for lung cancer drug testing can only generate one test result at a time, requiring multiple tests to identify the most suitable drug, thus consuming significant time and resources.
Innovation Solution
A drug testing platform with a microfluidic chip and stretching device that simulates lung environment breathing motion, incorporating multiple test areas and shunt units to conduct multiple tests simultaneously, allowing drugs to interact with lung cancer cells and generate multiple test results in a single run.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a single microfluidic chip is used for drug testing, then the device complexity is reduced, but the productivity is limited to one test result at a time
Solution Approach 1:
The microfluidic chip is divided into multiple independent test units (first test unit, second test unit, third test unit, fourth test unit) that can operate simultaneously. Each test unit contains separate microfluidic channels and chambers for different drug-cell interactions, enabling parallel processing of multiple tests without significantly increasing overall device complexity.
Solution Approach 2:
Multiple test units are integrated into a single microfluidic chip platform, combining the functionality of multiple separate testing devices into one unified system. This merging approach enables simultaneous generation of multiple test results while maintaining a relatively simple overall device structure through shared components such as the stretching device and common fluid supply systems.
2Loss of time
If multiple tests are conducted sequentially using a single microfluidic chip, then the device complexity remains low, but the loss of time increases significantly
Solution Approach 1:
The testing system is segmented into multiple parallel test units that can conduct drug screening tests simultaneously. The first test unit tests drug A on cell type 1, the second test unit tests drug B on cell type 2, the third test unit tests drug C on cell type 3, and the fourth test unit tests drug D on cell type 4, all occurring at the same time, thereby dramatically reducing the total screening time compared to sequential testing.
Solution Approach 2:
The system transitions from sequential testing (one-dimensional time progression) to parallel testing by adding a spatial dimension with multiple simultaneous test units. This dimensional expansion allows multiple drug-cell interactions to occur concurrently, transforming the time-consuming sequential process into an efficient parallel process that completes all tests simultaneously.
3Measurement precision
If a microfluidic chip simulates lung breathing motion, then the measurement precision of drug effects is improved, but the device complexity increases due to additional stretching mechanisms
Solution Approach 1:
The stretching device is designed as a universal mechanism that can simultaneously apply mechanical stretching to all four test units through a single driving unit. This multi-functional design allows the stretching device to serve all test units concurrently, improving the measurement precision of drug effects under simulated lung breathing conditions without proportionally increasing device complexity, as one stretching mechanism serves multiple purposes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform efficiently obtains nine test results simultaneously, accurately simulating lung environment mechanics and drug interactions, reducing the time and resources needed for drug screening.
Implementation Method 1
The stretching device is configured to stretch and contract the test unit in a manner of a reciprocal motion, thereby making degree of deformation of each of the first test area, the second test area, the third test area, the fourth test area, the fifth test area, the sixth test area, the seventh test area, the eighth test area, and the ninth test area to be same during the reciprocal motion
Data Source
AI summary
A drug testing platform for simulating a lung environment includes a microfluidic chip and a stretching device. The microfluidic chip defines a microfluidic channel structure. The microfluidic channel structure includes a test unit, a cell shunt unit and a drug shunt unit. The stretching device is configured to stretch and contract the test unit in a manner of a reciprocal motion, thereby making degree of deformation of a plurality of test area of the test unit to be same during the reciprocal motion. The drug testing platform for simulating the lung environment according to the present disclosure may configure an environment that simulates a breathing motion of a human lung, and obtain multiple results within a single test.